Caribou Biosciences is a pioneering clinical-stage biopharmaceutical company specializing in CRISPR genome-editing technology. The company is committed to developing innovative therapies aimed at treating patients with severe diseases, particularly through the advancement of off-the-shelf cell therapies derived from its CAR-T cell therapy platform. With a focus on precision and efficacy, Caribou is dedicated to making these transformative treatments readily available for patients suffering from hematologic malignancies. The company fosters a collaborative and inclusive work environment, encouraging diverse perspectives and engagement among its team members, who can work from its headquarters in Berkeley, California, or remotely.